Fate Therapeutics, Inc. Share Price

Equities

FATE

US31189P1021

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 21/06/2024 BST 5-day change 1st Jan Change
3.76 USD +4.74% Intraday chart for Fate Therapeutics, Inc. +4.16% +0.53%
Sales 2024 * 5.82M 460M Sales 2025 * 5.39M 426M Capitalization 428M 33.81B
Net income 2024 * -201M -15.88B Net income 2025 * -222M -17.54B EV / Sales 2024 * 34.2 x
Net cash position 2024 * 229M 18.11B Net cash position 2025 * 153M 12.07B EV / Sales 2025 * 51.1 x
P/E ratio 2024 *
-2.12 x
P/E ratio 2025 *
-2.1 x
Employees 181
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.42%
More Fundamentals * Assessed data
Dynamic Chart
Piper Sandler Upgrades Fate Therapeutics to Overweight From Neutral, Adjusts Price Target to $6 From $4 MT
Fate Therapeutics, Inc. Appoints J. Scott Wolchko as Principal Financial and Accounting Officer CI
Fate Therapeutics, Inc. Announces Chief Financial Officer Changes CI
Certain Restricted Stock Units of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Stock Options of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Pre-Funded Warrants of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Class A Convertible Preferred Stock of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Common Stock of Fate Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating MT
Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating MT
Transcript : Fate Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (FATE) FATE THERAPEUTICS Reports Q1 Revenue $1.9M MT
Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-The-Shelf FT819 CAR T-Cell Program CI
Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting CI
More news
1 day+4.74%
1 week+4.16%
Current month+2.17%
1 month+9.62%
3 months-43.12%
6 months+9.94%
Current year+0.53%
More quotes
1 week
3.20
Extreme 3.2
3.81
1 month
3.20
Extreme 3.2
4.19
Current year
3.20
Extreme 3.2
8.83
1 year
1.63
Extreme 1.63
8.83
3 years
1.63
Extreme 1.63
97.43
5 years
1.63
Extreme 1.63
121.16
10 years
1.46
Extreme 1.46
121.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 26/04/07
Chairman 75 31/10/11
Chief Tech/Sci/R&D Officer - 07/10/18
Members of the board TitleAgeSince
Director/Board Member 58 16/03/14
Director/Board Member 57 31/07/13
Chairman 75 31/10/11
More insiders
Date Price Change Volume
21/06/24 3.76 +4.74% 8,303,815
20/06/24 3.59 +5.28% 2,557,766
18/06/24 3.41 -4.48% 3,018,303
17/06/24 3.57 -1.11% 2,876,712

Delayed Quote Nasdaq, June 21, 2024 at 09:00 pm

More quotes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.76 USD
Average target price
6.786 USD
Spread / Average Target
+80.47%
Consensus